BOSTON, March 11 Replikins, Ltd. has announced developmentof a chemically synthesized vaccine specific to a Taura Syndrome virusstructure based on its patented Replikins(TM) technology. When the vaccine wasadministered orally to shrimp, 91% survived a challenge by the lethal Tauravirus. The specificity of the protective effect was established in controlgroups by chemically blocking the active regions in the vaccine, and as aresult the protective effect was lost in these control groups. Theeffectiveness of this vaccine, and its rapid production cycle (7 days),represent an important proof of concept for developing vaccines against arange of rapidly replicating high lethality virus outbreaks.
For counteracting emerging infectious disease, early detection and rapidresponse are critical. Replikin contributions to date are both in earlydetection and rapid response: 1) Advance warning previously was not possibleuntil it was found in H5N1 influenza that an increase in the virus replikinconcentration signalled one year in advance that the outbreak was coming, andindicated the country in which this would occur (FluForecast(TM), Indonesia).2) The production of vaccines by other methods has required 3 to 12 months, bywhich time the epidemic may have come and gone, or the vaccine effectivenessreduced or lost because the target changed due to mutation. In contrast, thereplikins vaccine found effective here was manufactured synthetically in 7days.
Viruses lethal to shrimp have been responsible for large losses toaquaculture worldwide. Replikins is forming a division to focus on theseviruses. The company is also pursuing development of synthetic vaccineproducts based on replikin epitopes, Syntopes(TM), for the control of fishhemorrhagic viruses and other lethal aquatic microorganisms,
Contact: Replikins Ltd., 38 The Fenway, Boston MA 02215.email: firstname.lastname@example.org Tel: 646-320-5910http://www.Replikins.com
This release was issued through eReleases(TM). For more information,visit http://www.ereleases.com.
SOURCE Replikins Ltd.